News | October 22, 2013

AngioScore to Present Data From First-In-Human Study of the Drug-Coated Scoring Balloon at TCT

balloon catheters cath lab clinical trial study angioscore angiosculpt scoring
October 22, 2013 — AngioScore Inc., a developer of angioplasty catheters for use in the treatment of cardiovascular disease, announced that preliminary data from the first-in-human (FIH) study (“Patent-C”) of the drug-coated AngioSculpt Scoring Balloon Catheter will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in San Francisco the week of Oct. 28.
This FIH trial enrolled 61 patients with coronary in-stent restenosis (ISR) at five international sites: four in Germany and one in Brazil. Bruno Scheller, M.D. and professor of interventional cardiology at Saarland University Hospital, Homburg, Germany, led the study, and along with Ulrich Speck of the Charité Hospital in Berlin, is one of the pioneers in the rapidly developing field of drug-coated balloons for the treatment of coronary and peripheral artery disease.
The drug-coated AngioSculpt FIH study was designed as a randomized controlled trial comparing the recently developed drug-coated AngioSculpt with the commercially available uncoated version of the AngioSculpt in patients presenting with significant restenosis in a previously implanted coronary bare metal stent. Patients underwent follow-up coronary angiography at six months to compare the rate of recurrent restenosis and late lumen loss (LLL) in both treatment arms. Additional study endpoints include the rate of major adverse cardiovascular events (MACE), clinically driven target lesion revascularization (TLR) and stent thrombosis for up to two years following the index procedure. All angiograms were analyzed by an independent core laboratory at the Cardiovascular Research Foundation in New York City.
The results of the FIM Study will be presented on the following date and times:
  • Oct. 28, 7:45 p.m. — Drug-coated AngioSculpt FIM Clinical Trial Results, “Featured Clinical Research Session,” Bruno Scheller — Moscone Convention Center West room 2002
  • Oct. 30, 7:00 a.m. — AngioScore Breakfast Symposium, Moscone Convention Center North room 121
  • Oct. 31, 9:52 a.m. — Drug-coated AngioSculpt FIM Clinical Trial Results - “Spotlight Session – Drug Coated Balloons,” Alexandre Abizaid, Moscone Convention Center North room 135
The AngioSculpt Scoring Balloon Catheter is an investigational device limited by applicable law to investigational use and not available for sale.
For more information:

Related Content

Cardiovascular Systems Inc. and OrbusNeich Announce FDA Clearance  of Sapphire II Pro 1mm Coronary Balloon
Technology | Balloon Catheter | March 21, 2018
Cardiovascular Systems Inc. (CSI) recently announced that the U.S. Food and Drug Administration (FDA) has granted 510(k...
Cardiovascular Systems Expands Product Portfolio for Peripheral and Coronary Interventions
News | Balloon Catheter | January 24, 2018
Cardiovascular Systems Inc. recently announced two new partnerships broadening the company’s product portfolio. CSI is...
Abbott recalls its NC Balloon catheters
News | Balloon Catheter | May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Videos | Balloon Catheter | November 16, 2016
A discussion with Todd Brinton, M.D., about the newly FDA-cleared Shockwave Medical Lithoplasty System, at the Transc
NuCryo Vascular, Next Generation Cryoplasty Inflation Device, PolarCath Balloon Dilatation System

PolarCath Balloon Dilatation System image courtesy of NuCryo Vascular

Technology | Balloon Catheter | March 28, 2016
NuCryo Vascular LLC announced the launch of the Next Generation Cryoplasty Inflation device. The device received U.S....
NuCryo Vascular, FDA clearance, next-gen, PolarCath System, cryoplasty inflation device
Technology | Balloon Catheter | January 12, 2016
NuCryo Vascular LLC announced that they have received U.S. Food and Drug Administration (FDA) 510(k) clearance on the...
Videos | Balloon Catheter | October 30, 2015
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford Uni
Overlay Init